First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma

Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.

EP: 1.Clinical Case: Intermediate-Risk, Metastatic Clear Cell Renal Cell Carcinoma

EP: 2.Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC

EP: 3.Risk Stratifying Patients with RCC: Making Informed Decisions

EP: 4.First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC

EP: 5.Treatment Recommendations for a 59-Year-Old Woman with RCC

EP: 6.Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy

EP: 7.Patient Case: Workup and Imaging in RCC

EP: 8.Patient Case: A 61-Year-Old Patient with Indolent Metastatic ccRCC

Now Viewing

EP: 9.First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma

EP: 10.Optimizing ICI and TKI Combinations + Dose Reductions

EP: 11.Indolent Metastatic ccRCC Disease Progression and Guideline Updates

EP: 12.Third-Line Therapy for Patients with ccRCC

EP: 13.Patient Case: A 58-year-old Man With Hematuria and Abdominal Pain

EP: 14.First-Line ICI-Based Combinations for mRCC With Sarcomatoid Features

Recent Videos